Gilead Sciences (GILD) Secures Canada Reimbursement Deal For PBC Therapy

• Gilead Sciences (NasdaqGS:GILD) reached a reimbursement agreement with the pan-Canadian Pharmaceutical Alliance for LYVDELZI in primary biliary cholangitis.
• The pact covers LYVDELZI, also known as seladelpar, for eligible PBC patients under Canadian public drug plans.
• This agreement follows Health Canada approval of LYVDELZI for PBC, widening potential access pathways for patients with this rare liver disease.
• The new LYVDELZI reimbursement framework in Canada is only one piece of the broader Gilead story investors are weighing today. We have also flagged 2 warning signs for Gilead Sciences.

Zooming out from Gilead Sciences to the broader shift in liver and immune disease treatment, some investors are also examining 36 healthcare AI stocks.

Gilead Sciences is a US based biopharmaceutical group focused on treatments for areas of unmet medical need. Adding a rare liver disease medicine like seladelpar into its portfolio extends its reach within immune and liver disorders beyond its more established therapeutic franchises.

3 things going right for Gilead Sciences that this headline doesn't cover.

What LYVDELZI reimbursement progress adds to the Gilead Sciences story

The Canadian reimbursement deal edges Gilead Sciences a little further toward the Narrative goal of building a third leg in liver and immunology, alongside HIV and oncology. It speaks directly to the catalyst that highlights Livdelzi expansion into liver disease as a potential contributor to a broader revenue mix. Against a backdrop where the group reported US$8,300m in third quarter 2026 revenue and a net loss of US$6,045m over the first nine months of 2026, access wins like this matter because they help turn pipeline talking points into reimbursed usage in a defined rare disease niche.

See how these catalysts shape Gilead Sciences' path to a $159 fair value.

For this update to be more meaningful in an investment checklist, the next proof points sit in how many Canadian provincial and federal plans actually list LYVDELZI and on what timetable, with some jurisdictions indicating potential reimbursement from 2027. Watching those formulary decisions and any disclosed patient uptake will show whether this access step merely maintains the current position or supports the longer term immunology and liver disease thesis for Gilead Sciences.

One question Gilead Sciences investors still have to answer

The missing piece is what the stream of cash flowing through Gilead Sciences suggests the whole enterprise might be worth compared with where the share price trades today. Find out exactly what Gilead Sciences is worth today based on its cash flows.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com